Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses

Rituximab, a B cell–depleting therapy, is indicated for treating a growing number of autoantibody-mediated autoimmune disorders. However, relapses can occur after treatment, and autoantibody-producing B cell subsets may be found during relapses. It is not understood whether these autoantibody-produc...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:JCI Insight
Hoofdauteurs: Jiang, Ruoyi, Fichtner, Miriam L., Hoehn, Kenneth B., Pham, Minh C., Stathopoulos, Panos, Nowak, Richard J., Kleinstein, Steven H., O’Connor, Kevin C.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Clinical Investigation 2020
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7453893/
https://ncbi.nlm.nih.gov/pubmed/32573488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.136471
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items